Design an outpatient heart failure rapid-optimization clinic: weekly GDMT titration…
- User
Design an outpatient heart failure rapid-optimization clinic: weekly GDMT titration ladder, labs cadence, and safety checks.
- Assistant
Outpatient Heart Failure Rapid-Optimization Clinic (HF-ROC)
Clinic Overview
Purpose: Accelerate GDMT optimization in stable HFrEF patients (EF ≤40%) to achieve ≥90% target doses within 6-8 weeks, reducing hospitalizations and improving outcomes (inspired by STRONG-HF trial). Weekly in-person or telehealth visits with pharmacist-led titration under cardiologist oversight.
Patient Eligibility:
- NYHA II-III, recently hospitalized or newly diagnosed HFrEF.
- euvolemic (weight stable ±2kg, no orthopnea).
- SBP ≥100 mmHg, HR 50-110 bpm, K⁺ ≤5.0 mEq/L, eGFR ≥30 mL/min.
- Exclusions: ACS <2 weeks, ICD/CRT candidate pending, active arrhythmia, severe CKD (eGFR <30).
Team: HF cardiologist, clinical pharmacist, nurse, dietician (PRN). Duration: 8 weekly visits, then transition to standard HF clinic. Metrics: Track % target GDMT dose, BNP trend, 6MWT, QoL (KCCQ).
Weekly Clinic Flow
- Pre-Visit (Patient): Daily home BP/HR/weight log; symptom diary (dyspnea, fatigue).
- Visit (30-45 min):
- Review logs/symptoms.
- Vitals: BP, HR, SpO2, weight, orthostatics.
- Labs/ECG review (see cadences).
- Titrate GDMT per ladder.
- Education/reinforce SGLT2i, loop diuretic if needed.
- Post-Visit: Rx updates, next appt auto-scheduled.
GDMT Titration Ladder
Four Pillars: ARNI (or ACEI/ARB if intolerant), Evidence-Based Beta-Blocker (EBBB: carvedilol/metoprolol succ succ/bisoprolol), MRA, SGLT2i.
Principles:- Titrate 1-2 agents/week if safety criteria met (below).
- Start all pillars Week 1 if stable.
- Targets: ACC/AHA 2022 guidelines.
- Loop diuretic: Continue at lowest effective dose; reduce 25-50% if euvolemic.
Week ARNI (Sac/Val) EBBB MRA (Spirono/Eplerenone) SGLT2i Notes 0 (Baseline) None None None None Start all if eligible. 1 24/26 mg BID Carvedilol 3.125 mg BIDOR Metop Succ 12.5-25 mg QDOR Bisoprolol 1.25 mg QD Spiro 12.5-25 mg QD Dapa/Empa 10 mg QD Add ivabradine if HR ≥70 on max EBBB. 2 ↑ to 49/51 mg BID Carvedilol ↑6.25 mg BIDOR Metop ↑50 mg QDOR Bisoprolol ↑2.5 mg QD Spiro ↑25 mg QD Continue target Vericiguat PRN if high-risk. 3 ↑ to 97/103 mg BID Carvedilol ↑12.5 mg BIDOR Metop ↑100 mg QDOR Bisoprolol ↑5 mg QD ↑ to 50 mg QD (split BID if needed) Continue Check adherence. 4 Target Carvedilol ↑25 mg BID (>85kg) or 50 mg BIDOR Metop ↑200 mg QDOR Bisoprolol ↑10 mg QD Target Continue 50% patients at target. 5-6 Maintain/ACEI switch if cough ↑ to target if not yet Maintain Continue Loop diuretic taper if stable wt. 7-8 Target Target Target Target ≥90% target doses; BNP goal < baseline. % Target Dose Calculation: (Actual dose / Target dose) × 100; average across pillars.
Labs Cadence
Frequent monitoring for hyperK/↓eGFR/worsening HF.
Test Baseline Weekly (Wks 1-4) Biweekly (Wks 5-8) Rationale CMP (Cr, K⁺, Na, BUN) ✓ ✓ ✓ Renal/K⁺ safety; hold titrations if Cr ↑>30%, K>5.5. BNP/NT-proBNP ✓ Every other wk Every other wk ↓>30% target; ↑ prompts echo/volume assess. CBC ✓ PRN (anemia) - Monitor for SGLT2i UTI. Mg ✓ PRN - BB tolerance. Lipid panel, HbA1c ✓ Wk 8 - SGLT2i benefits. ECG ✓ Wk 4 & 8 PRN (symptoms) QT/arrhythmia. Thresholds: eGFR ↓>25% or Cr ↑>0.3 mg/dL → hold/down-titrate ARNI/MRA.
Safety Checks & Escalation
Green Light (Titrate):
- Asymptomatic or improved.
- SBP ≥100 mmHg (≥90 if baseline low), HR 50-100 bpm.
- Wt ±2kg from baseline.
- K⁺ 3.5-5.5, eGFR stable (±20%).
- BNP stable/↓.
Yellow Light (Hold, reassess):
- Mild symptoms (↑dyspnea 1 NYHA class).
- SBP 90-99, HR <50 or >110.
- K⁺ 5.1-5.5 or eGFR ↓10-25%.
Red Light (Escalate: ED/Admission):
- SBP <90, HR <45/>120.
- K⁺ >5.5/>6.0 (urgent).
- eGFR ↓>30%, acute wt gain >3kg, worsening NYHA IV.
- New angina, syncope, arrhythmia.
Adverse Event Management:
Issue Action HyperK Hold MRA/ARNI, kayexalate PRN, recheck 48h. ↓BP Hold titrated agent 24-48h, ↑ salt/fluids, down-titrate BB. AKI Hold ARNI/MRA/SGLT2i, loop ±. Angioedema Switch ACEI/ARNI → ARB. Outcomes Tracking & Handover
- Weekly Audit: Titration success, adverse events.
- Wk 8: Echo if EF change suspected; handover to standard clinic q3-6mo.
- Evidence Base: STRONG-HF (rapid uptitration safe/feasible), CHAMP-HF (median 2mo to target too slow).
This protocol is templated for EHR integration (e.g., auto-alerts for labs/safety). Implement with IRB if research. Questions?
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.